# Pediatric Constipation and Encopresis

## Overview

Constipation accounts for approximately 3-5% of all pediatric outpatient visits and about 25% of pediatric gastroenterology referrals. Functional constipation, which has no underlying organic cause, accounts for more than 95% of cases. Encopresis (fecal incontinence) is the involuntary passage of stool, usually due to fecal impaction with overflow, and affects roughly 1-3% of children aged 4-12 years. Peak onset of functional constipation occurs at three critical periods: introduction of solid foods, toilet training, and school entry. Early recognition and aggressive treatment prevent the vicious cycle of stool withholding.

## Pathophysiology of Functional Constipation

The cycle begins when a hard or painful stool leads to withholding behavior driven by fear of defecation. Withholding leads to rectal distension, decreased rectal sensation, and further stool retention. Progressive rectal distension causes loss of the normal defecation urge and overflow incontinence (encopresis). Chronic rectal distension may also impair internal sphincter relaxation. The result is a self-reinforcing vicious cycle: pain causes withholding, which produces harder stool, which causes more pain and more withholding.

## Clinical Presentation

### Symptoms

Children present with infrequent bowel movements (fewer than 3 per week), large, hard, or painful stools, and characteristic stool withholding postures such as stiffening, crossing legs, hiding in corners, or toe-walking. Abdominal pain, bloating, and decreased appetite are common. Encopresis manifests as soiling of underwear with loose stool from overflow incontinence, which is not volitional. Rectal bleeding from anal fissures may also occur.

### Rome IV Criteria (Functional Constipation, Ages 4 Years and Older)

The Rome IV criteria require at least 2 of the following for at least 1 month: 2 or fewer defecations per week, at least 1 episode of fecal incontinence per week, history of retentive posturing or excessive volitional stool retention, history of painful or hard bowel movements, presence of a large fecal mass in the rectum, or history of large-diameter stools that may obstruct the toilet.

<image>Pathophysiology diagram of the functional constipation cycle showing hard stool causing painful defecation, leading to stool withholding behavior, progressive rectal distension and decreased sensation, further stool accumulation and hardening, eventual overflow incontinence (encopresis), and the self-reinforcing nature of this cycle</image>

## Red Flags for Organic Causes

### When to Suspect Hirschsprung Disease

The most important clue is failure to pass meconium within 48 hours of birth. Other features include constipation from birth (neonatal onset), an empty rectum on digital examination with stool higher up and an undilated rectum, explosive stool after digital exam (the "squirt sign"), failure to thrive, and abdominal distension. Hirschsprung-associated enterocolitis (fever, bloody diarrhea, abdominal distension) is a medical emergency. Contrast enema shows a transition zone with a narrow distal segment and dilated proximal bowel. Diagnosis is confirmed by rectal suction biopsy showing absence of ganglion cells and hypertrophied nerve fibers, with a negative calretinin stain. Treatment is a surgical pull-through procedure (Soave, Duhamel, or Swenson).

### Other Organic Causes

Additional organic causes include hypothyroidism, hypercalcemia, spinal cord anomalies (tethered cord, suggested by sacral dimple or gluteal asymmetry), celiac disease, cystic fibrosis (meconium ileus, distal intestinal obstruction syndrome), anorectal malformations (imperforate anus, identified at birth), lead poisoning, medications (opioids, anticholinergics, iron supplements), and cow's milk protein allergy in infants with chronic constipation.

## Diagnostic Evaluation

History and physical examination are usually sufficient, and no routine imaging or laboratory tests are needed for typical functional constipation. Digital rectal exam assesses for rectal impaction, anal tone, and rectal caliber; a large stool mass in a dilated rectum suggests functional constipation, while an empty ampulla raises concern for Hirschsprung disease. Abdominal X-ray is not routinely recommended but may be useful when rectal exam is deferred or refused; it shows fecal loading but has poor interrater reliability. Laboratory tests (TSH, celiac panel, lead level, calcium, electrolytes) are indicated when an organic cause is suspected. Contrast enema and rectal biopsy are obtained for suspected Hirschsprung disease. Anorectal manometry demonstrating an absent rectoanal inhibitory reflex (RAIR) also suggests Hirschsprung disease. Spinal MRI is warranted when neurologic signs or sacral anomalies are present.

## Treatment

### Phase 1: Disimpaction (If Impacted)

The impaction must be cleared before starting maintenance therapy. Oral disimpaction is preferred if the child can tolerate it, using PEG 3350 at 1-1.5 g/kg/day for 3-6 days (clean-out dose) or high-dose mineral oil. Rectal disimpaction is used when oral methods fail or for severe impaction, using pediatric sodium phosphate enemas (with caution due to risk of electrolyte derangements including hyperphosphatemia and hypocalcemia), glycerin suppositories in infants, or normal saline enemas. Soap suds enemas, tap water enemas (electrolyte risk), and milk and molasses enemas in small children should be avoided. Manual disimpaction under sedation is rarely needed and reserved for massive impaction refractory to other methods.

### Phase 2: Maintenance Therapy

| Medication | Class | Dose | Age Considerations | Notes |
|-----------|-------|------|-------------------|-------|
| PEG 3350 (MiraLAX) | Osmotic | 0.4-0.8 g/kg/day (maintenance); 1-1.5 g/kg/day (clean-out) | Off-label <17 yr but widely used | First-line; safe for long-term use |
| Lactulose | Osmotic | 1-3 mL/kg/day divided BID | Preferred in infants | May cause more bloating/gas |
| Mineral oil | Lubricant | 1-3 mL/kg/day | Not for <1 year or aspiration risk | Can be mixed with juice |
| Senna (Senokot) | Stimulant | 2.5-7.5 mL/day (age-dependent) | Short-term adjunctive use | Not first-line maintenance |
| Bisacodyl | Stimulant | 5-10 mg/day (>2 years) | Short-term use only | Available as suppository |
| Glycerin suppository | Osmotic/local | 1 suppository PRN | Safe in infants | For acute relief only |

PEG 3350 (MiraLAX) is the first-line maintenance agent at 0.4-0.8 g/kg/day, titrated to a goal of 1-2 soft stools per day. It is an osmotic laxative with minimal systemic absorption that is mixed in water, juice, or clear liquid and is tasteless and odorless. While FDA-approved only for ages 17 and older, it is widely used off-label in younger children and is safe for long-term use. Lactulose is an osmotic alternative that may cause more bloating and gas and is used in infants. Mineral oil is a lubricant option but is not appropriate for children under 1 year or those with aspiration risk. Stimulant laxatives (senna, bisacodyl) are for short-term adjunctive use and are not first-line for daily maintenance. Fiber supplementation should target an intake of age plus 5 grams per day, with dietary fiber preferred over supplements. Adequate fluid intake should be encouraged, though it is not independently proven to resolve constipation.

### Phase 3: Behavioral Management

A regular toileting routine has the child sit on the toilet for 5-10 minutes after meals (utilizing the gastrocolic reflex), 2-3 times daily. Positive reinforcement with sticker charts and rewards should target sitting on the toilet, not producing a stool. A foot stool provides proper positioning with feet supported, mimicking squatting and optimizing the anorectal angle. Education should emphasize that overflow incontinence is not the child's fault, reducing blame and shame. Addressing withholding behavior involves reassuring the child that medication will make stools soft and pain-free, reducing the fear of defecation.

### Duration of Treatment

Maintenance therapy is typically needed for a minimum of 6-24 months. Gradual weaning should begin only once regular bowel habits have been established for at least 2 months of daily soft stools. Premature weaning is the most common cause of relapse. Recurrences are common (approximately 50%), and families should be counseled about this expectation.

<image>Treatment algorithm for pediatric functional constipation showing three phases: Phase 1 disimpaction (oral PEG clean-out preferred, rectal disimpaction if needed), Phase 2 maintenance (daily PEG 3350, dietary fiber, adequate fluids), and Phase 3 behavioral management (regular toileting schedule, positive reinforcement, foot stool positioning), with emphasis on 6-24 months minimum treatment duration</image>

## Encopresis Management

Encopresis is overflow incontinence, not a behavioral problem, and the child cannot control it. Treatment follows the same three-phase approach of disimpaction, maintenance, and behavioral management. Education is paramount: the mechanism must be explained to both parents and child, and blame must be removed. Referral to behavioral health is appropriate when there is significant family conflict, anxiety, or psychosocial issues. Non-retentive fecal incontinence is a rare condition involving normal bowel movements in inappropriate places without impaction, often associated with behavioral or developmental issues, and should be referred for behavioral therapy.

## Infant Constipation

Infant dyschezia involves straining and crying for 10 or more minutes before passage of soft stools in infants younger than 9 months. This is a normal developmental phenomenon and not true constipation; no treatment is needed. True infant constipation presents with hard, pellet-like stools and warrants evaluation for organic causes (Hirschsprung disease, hypothyroidism, cystic fibrosis). Management includes glycerin suppositories for acute relief and lactulose for maintenance; PEG should be avoided in infants due to limited data. A cow's milk protein allergy trial should be considered in formula-fed infants with chronic constipation.

## Clinical Pearls

Functional constipation is a clinical diagnosis, and abdominal X-rays should not be routinely ordered because they have poor interrater reliability and rarely change management. The most important red flag for Hirschsprung disease is failure to pass meconium within 48 hours of birth, which should always be asked about in the history. Overflow encopresis is involuntary, and parents must understand this is not defiance or laziness; removing blame is itself therapeutic. PEG 3350 is safe for long-term use, and premature discontinuation is the number one cause of relapse. A trial of cow's milk elimination should be considered in infants and toddlers with refractory constipation, as milk protein allergy can present as constipation. Stool withholding postures (stiffening legs, hiding in corner) are often misinterpreted by parents as straining to defecate, and careful history clarifies this distinction.

## Key Controversy: Duration of Maintenance PEG Therapy

There are no clear evidence-based guidelines on the optimal duration of maintenance therapy. Expert consensus recommends a minimum of 6 months after regular bowel habits are established, with many children needing 12-24 months or longer. Parental concerns center on long-term safety of PEG in children and fear of "dependence" on laxatives. Evidence supports PEG safety in children, with no significant electrolyte disturbances, no mucosal changes, and minimal systemic absorption. The FDA has not formally approved PEG 3350 for children under 17 years, despite it being the most widely used laxative in pediatric practice. Some families resist long-term medication use and wean prematurely, leading to relapse and recurrent impaction. Future research directions include biomarkers for safe medication discontinuation, rectal compliance testing, and the role of the gut microbiome in functional constipation.

<image>Long-term outcomes data for pediatric functional constipation showing relapse rates after early versus prolonged PEG maintenance therapy, factors predicting successful medication weaning (regular toileting habits, resolved withholding behavior, normalized rectal sensation), and the importance of gradual dose reduction over abrupt discontinuation</image>

## References
- Tabbers MM, et al. Evaluation and Treatment of Functional Constipation in Infants and Children (ESPGHAN/NASPGHAN). J Pediatr Gastroenterol Nutr. 2014;58(2):258-274.
- Benninga MA, et al. Childhood Functional Gastrointestinal Disorders: Neonate/Toddler (Rome IV). Gastroenterology. 2016;150(6):1443-1455.
- Nurko S, Zimmerman LA. Evaluation and Treatment of Constipation in Children and Adolescents. Am Fam Physician. 2014;90(2):82-90.
- Gordon M, et al. Osmotic and Stimulant Laxatives for the Management of Childhood Constipation. Cochrane Database Syst Rev. 2016;(8):CD009118.
- Koppen IJN, et al. Management of Functional Constipation in Children: Therapy in Practice. Paediatr Drugs. 2015;17(5):349-360.